---
layout: post
title: "恒瑞医药：用于治疗成人糖尿病的SHR-1816注射液临床试验获批"
date: 2022-03-09 17:04:35 +0800
categories: jiemianxinwen
tags: 界面新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600276" data-code="600276|1|1" data-code2="600276|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600276&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600276_0" data-code="K 600276|1|1" data-code2="K 600276|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>恒瑞医药3月9日晚间公告，子公司北京盛迪医药、上海恒瑞医药收到国家药监局核准签发关于SHR-1816注射液的《药物临床试验批准通知书》。SHR-1816注射液临床拟皮下注射用于治疗成人糖尿病。经查询，目前国内外尚无同类品种上市，亦无相关销售数据。截至目前，SHR-1816注射液相关研发项目累计已投入研发费用约4359万元。<br /></p><p class="em_media">（文章来源：界面新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203092303205189>

[返回界面新闻新闻](//finews.withounder.com/category/jiemianxinwen.html)｜[返回首页](//finews.withounder.com/)